# Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

> **NCT03676231** · PHASE2 · TERMINATED · sponsor: **Second Genome** · enrollment: 9 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** SGM-1019
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03676231
- **Lead sponsor:** Second Genome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-18
- **Primary completion:** 2019-05-01
- **Final completion:** 2019-05-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study terminated due to a safety event which rendered the risk-benefit profile in NASH to no longer be adequately favorable
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676231, "Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03676231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*